For stabilized patients undergoing complex PCI, left ventricular unloading with an Impella CP microaxial flow pump ...

A massive international study could upend 40 years of heart attack treatment. Researchers found that beta blockers—routinely prescribed after uncomplicated heart attacks—offered no real benefit for ...

Researchers have developed a scalable bioreactor-based system to produce cardiac organoids that successfully integrated into ...

A domestic collaborative research study has been published that prospectively analyzed the prevalence and prognosis of ...

Early report on modular BioVAT patches in advanced stage C or D disease ...

Sleep breathing disorders (SBDs)—including obstructive sleep apnoea, central sleep apnoea and sleep-related hypoventilation syndromes—represent a major yet under-recognised contributor to global ...

BioCardia ®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from ...

Germany: Interim findings from an early-stage study suggest that BioVAT, a tissue-engineered cardiac muscle patch therapy, may help remuscularize the heart in patients with advanced heart ...

Repairon, a biotechnology company developing regenerative cardiac therapies, today announced that clinical results evaluating its engineered human heart muscle tissue for patients with advanced heart ...

The risk for major adverse cardiovascular events appeared similar between older patients treated with 5-aminosalicylic acid ...

In modern cardiology, one of the greatest challenges is not treating heart attacks-but identifying silent coronary artery ...

Real-world analysis of three years of closed claims data from Symphony Health, focused on the third year of the study (2023-2024), comprised of ...